Table 3.
Number of study participants who had an immune status reassignment
| Participant groups | Nº of participants whose immune status was reassigned | Immune status reported by participant (Initial) | Immune status following defined criteria application (Final) | ||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 0 | 1 | 2 | ||
| CDG group (Total) | 56 out of 209 (26.6%) | 42 (75%) | 9 (16.1%) | 5 (8.9%) | 9 (16.1%) | 33 (58.9%) | 14 (25%) |
| PMM2-CDG group | 40 out of 122 (32.8%) | 27 (67.5%) | 8 (20%) | 5 (12.5%) | 8 (20%) | 20 (50%) | 12 (30%) |
| Non-PMM2-CDG group | 16 out of 87 (18.4%) | 15 (93.7%) | 1 (6.3%) | 0 | 1 (6.3%) | 13 (81.2%) | 2 (12.5%) |
| Control group | 103 out of 349 (29.5%) | 68 (66%) | 23 (22.3%) | 12 (11.7%) | 25 (24.3%) | 71 (68.9%) | 7 (6.8%) |
Number and percentages of participants whose answer to the first question about immunological involvement (highlighted in light red in Fig. 2) was different to the follow-up information provided in specific immune-related manifestations sections
0, without immunological involvement; 1, with Immunological involvement; 2, unsolved immune status